FCF Biotech Venture Capital Monitor – USA 10/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of October 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 19,658m
  • Compared to September 2022 the financing volume decreased by almost 29% (27,667m vs. 19,658m)
  • The top 5 deals exceed USD 273m each, the largest transaction amounted to USD 401m with ElevateBio
  • Aiolos Bio has the highest transaction Volume of USD 245m in October, followed by MapLight USD 225m and Rakuten Medical USD 182m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and Google Ventures (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link.